|
Promising Preclinical Data to a Possible Antidiabetic Drug
|
|
| Author:
|
RUSUL AHMED TARIQ, BASMA TALIB AL-SUDANI, INAM SAMEH ARIF
|
| Abstract:
|
Purpose: Current studies propose that SIRT1 activating compounds are a promising class of anti-diabetic drugs, while their mechanism of action remains elusive. The main goal of this study is to determine the role of SIRT1 aptamer, a selective activator of SIRT1, as a potential therapy for type 2 diabetes mellitus.
Experimental design: Using in vivo (animal experiments) approach, the role of SIRT1 agonists (SIRT1 aptamer) as antidiabetic agent in diabetic rats (pre-treatment with 160mg/kg intraperitoneal injection of alloxan) was studied. Blood glucose level and SIRT1 activity was assessed after treating the rats with different concentrations of SIRT1 aptamer (12.5, 25 and 50µM) at 24hr, 48hr and 8 days.
Results: Results showed that the increase of glucose level in diabetic rats was greatly abrogated by exposing the rats to 50 µM of SIRT1 aptamer, and this type of SIRT1 agonist can activate in particularly of SIRT1 activity more than twice its value compared with 200µM Resveratrol.
Conclusions: Taken both our results detect an essential role for SIRT1 aptamer to activate SIRT1 enzyme and controlled the glucose level in vivo. SIRT1 aptamer could therefore be a promising therapeutic strategy to treat type 2 diabetes mellitus.
Abbreviation: T2DM, type 2 diabetes mellitus; SIRT1, Sirtuin type 1;Apt; aptamer PGC-1a, peroxisome proliferator-activated receptor-? coactivator-1a; FOXO, forkhead box O;RSV, Resveratrol.
|
| Keyword:
|
SIRT1 activity, Resveratrol, T2DM.
|
| EOI:
|
-
|
| DOI:
|
https://doi.org/10.31838/ijpr/2020.12.04.378
|
| Download:
|
Request For Article
|
|
|